Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




BD Advances Entry into NGS with Acquisition of GenCell Biosystems

By LabMedica International staff writers
Posted on 26 Oct 2014
Leading medical technology company Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA) has acquired GenCell Biosystems (Limerick, Ireland), a privately-held biotech company that has developed proprietary technologies that address key biological analysis protocols —from library preparation of Next Generation Sequencing (NGS) to genotyping for agricultural applications.

“We are excited with the GenCell Biosystems acquisition as it provides BD entry into the Next Generation Sequencing market, a fast-growing segment with the potential to have a significant impact on healthcare,” said Linda Tharby, Group President, BD, “The acquisition gives BD access to the NGS market with a differentiated platform that will provide a base to further grow our genomics offerings.”

GenCell Biosystems is an Enterprise Ireland-supported company whose headquarters and manufacturing are based in Limerick (Ireland), and operates a USA marketing, sales, and service group in Madison (WI, USA). More...
Founded in 2011, GenCell has created an automated platform that has the potential to address key unmet customer needs in library preparation for NGS.

Kieran Curran, CEO and founder of GenCell, commented, “We are looking forward to joining with BD to provide great solutions for our current and future customers in Next Generation Sequencing. In a short amount of time we have been able to move CLC technology from concept to product. We believe we will now be able to scale up and introduce further transformative innovation in NGS-related segments.”

Financial details on the acquisition are not being disclosed at this time. The expected impact of this transaction will be reflected in guidance that will be communicated on BD’s fourth quarter earnings call.

Related Links:

Becton, Dickinson and Company (BD)
GenCell Biosystems



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.